Apheresis (Therapeutic Pheresis) — NCD 82 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 82 governing apheresis (therapeutic pheresis) coverage, with an effective date of March 7, 2026. Here's what billing teams need to know before submitting claims.

CMS apheresis coverage policy under NCD 82 Medicare defines 13 covered indications — from plasma exchange for myasthenia gravis to treatment of Guillain-Barré Syndrome — with strict facility and physician supervision requirements. This policy does not list specific CPT or HCPCS codes, which creates real documentation and charge capture challenges your billing team needs to address now.

Quick-Reference Table

CMS Apheresis Coverage Criteria and Medical Necessity Requirements 2026

NCD 82 is the National Coverage Determination that governs Medicare coverage of therapeutic apheresis. The policy covers apheresis only as an autologous procedure — blood taken from the patient, processed, and returned to the same patient in one continuous procedure. If your team has been billing anything that involves pre-donated blood transfused later, that falls outside this coverage policy entirely.

Medical necessity under NCD 82 is indication-specific. CMS doesn't offer a broad "medically necessary apheresis" standard. Instead, each covered condition carries its own implied standard — and several require documented treatment failure before Medicare pays. For example, plasma exchange for TTP is covered only as a "last resort." The same applies to rheumatoid vasculitis, SLE, scleroderma, and polymyositis. That language isn't decorative — it's a documentation requirement.

This is where claim denial risk concentrates. If your medical records don't document that conventional therapy failed before apheresis was ordered, Medicare can — and will — deny on medical necessity grounds. Build that documentation into your pre-authorization workflow before March 7, 2026.

Facility requirements are equally strict. Apheresis is covered only in a hospital setting (inpatient or outpatient) or a non-hospital clinic that meets all three conditions: a physician present at all times during patient care hours, each patient under the direct care of a physician, and all non-physician services under direct personal physician supervision. A physician being "available by phone" does not satisfy this. Document actual physical presence.

Whether prior authorization is required depends on your MAC's local policies and any supplemental plan requirements. NCD 82 itself doesn't mandate prior auth, but your Medicare Administrative Contractor may have added LCD-level requirements on top of this national determination. Check with your MAC before assuming the national NCD is the only bar to clear.

CMS Apheresis Exclusions and Non-Covered Indications

NCD 82 doesn't frame exclusions the way many commercial policies do. It doesn't list a set of "non-covered" conditions. Instead, the policy limits coverage to 13 specific indications. Anything outside that list — any apheresis performed for a condition not enumerated — is not covered under Medicare.

This matters because apheresis has a broad and growing clinical use base. Conditions like ANCA-associated vasculitis, neuromyelitis optica, and certain autoimmune encephalitis cases see apheresis used in clinical practice. None of those appear in NCD 82. If your providers are ordering therapeutic pheresis for indications beyond the 13 listed, those claims will not pass Medicare coverage policy without a successful appeals argument or an Advance Beneficiary Notice (ABN) process.

Issue ABNs before performing apheresis for any off-list indication. Don't bill and appeal — that's the slow, expensive path. The ABN protects both your reimbursement and the patient's financial expectations.

Coverage Indications at a Glance

CMS Apheresis Billing Guidelines and Action Items 2026

The real issue with apheresis billing under NCD 82 isn't the coverage criteria — it's the documentation chain. Most denials on therapeutic pheresis claims trace back to missing or weak clinical justification at the chart level, not the wrong code. Here's what your team needs to do before the March 7, 2026 effective date.

If you're unsure how your current apheresis volume maps against these criteria, bring your compliance officer into the review before March 7, 2026. The supervision and "last resort" documentation requirements create audit risk that's worth a formal internal look.

CPT, HCPCS, and ICD-10 Codes for Apheresis Under NCD 82

NCD 82 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is a known gap in this coverage policy and a practical problem for apheresis billing.

The absence of enumerated codes means your billing team carries more responsibility for matching the procedure to the correct code — and for defending that match in the event of an audit. This is not uncommon for older NCDs, but it creates real risk.

Your immediate action: Work with your coding team or a billing consultant to confirm you're using the appropriate CPT codes for each apheresis sub-type. The specific codes your practice uses should align with the AMA's CPT code set for therapeutic apheresis procedures and should be consistent across all claims for the same procedure type.

Because no codes are specified in the policy data, PayerPolicy is not able to list them here. Do not rely on code tables from older resources — verify against the current CPT code set and confirm applicability with your MAC. If this policy applies to a significant portion of your claim volume, talk to your billing consultant before the effective date of March 7, 2026.